Spin-off projects seeking to pitch are pre-selected by a selection committee comprising life sciences experts from academia, industry, and the investor community to ensure quality and maximise impact. The committee assesses nominated spin-offs, reviews presentations from the selected companies, and provides coaching to presenters, many of whom are giving their first market-facing pitch.
The selection committee consists of the following members:
- Carmen Correa Martin, Erasmus MC
- Daisy Flamez, University of Ghent
- Clemens Ostrowicz, University Luxembourg – (LCSB)
- Bram Perdu, KU Leuven Research & Development – chair selection cie
- Esther Rodijk, TTT MedTech and UTwente
- Veronique Vermeeren, UHasselt
- Tessy Korthout, Oncode Institute
- Paul Soons, Orthogonaal Advies
- Peter Roevens, In2 Drug Targets
and is supported in the coaching by:
- Simone Hermans, Health Holland
- Viggo Van Tendeloo, Johnson&Johnson
- Bram Janssen, Arnold&Siedsma
Past members selection committee:
- Rudi Cuyvers, KU Leuven Research & Development Spin-off and Innovation
- Shobhit Dhawan, Oncode Oncology Bridge Fund
- Aard Groen, University of Groningen Centre of Entrepreneurship
- Louise Hoppel, Radboud UMC
- Annick Houbrechts, Interface Entreprises, University of Liège
- Jasper Keyman, Erasmus MC (University of Rotterdam)
- Henri Theunissen, Brightlands (University of Maastricht)
- Thijs van den Munckhof, UNIIQ / University of Leiden
- Griet VanPoucke, VIB
- Marcos Casado, INKEF Capital